Klotho Neurosciences Plunges 10.95% on Warrant Price Cut

On June 11, 2025, Klotho Neurosciences experienced a significant drop of 10.95% in pre-market trading, reflecting investor reactions to recent corporate developments.

Klotho Neurosciences recently amended the terms of its public warrants, temporarily reducing the exercise price from $3.49 to $1.35. This change, effective until a specified date, aims to provide warrant holders with a limited-time opportunity to exercise their warrants at a lower cost. The amendment does not alter other terms of the warrants, maintaining the same conditions as before.

The company's focus on increasing longevity and healthy life span through the replacement of the silenced gene alpha-Klotho (α-Klotho) continues to drive its research and development efforts. This strategic direction is part of Klotho Neurosciences' broader mission to advance biological products and therapies.